M. Hermans

发表

Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.

S. Brichard, V. Preumont, M. Hermans, 2010, Diabetes & metabolism.

Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.

M. Hermans, P. Oriot, N. Menghoum, 2021, Diabetes & metabolic syndrome.

Glycemic Control in Type 1 Diabetes: A cross-sectional study in 1,200 Belgian patients

M. Hermans, M. Buysschaert, I. Paris, 1998, Diabetes Care.

PREDICTIVE FACTORS ASSOCIATED WITH PRIMARY FAILURE TO EXENATIDE AND NON GOAL ATTAINMENT IN PATIENTS WITH TYPE 2 DIABETES

V. Preumont, M. Hermans, M. Buysschaert, 2012, Acta clinica Belgica.

Hyperadiponectinaemia in anorexia nervosa

S. Brichard, M. Hermans, C. Beguin, 2003, Clinical endocrinology.

Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium.

M. Hermans, M. Buysschaert, I. Paris, 1997, Diabetes & metabolism.

Modulation of the effect of acetylcholine on insulin release by the membrane potential of B cells.

M. Hermans, J. Henquin, W. Schmeer, 1987, Endocrinology.

The [C282Y/wt] heterozygous HFE genotype is associated with lower blood pressure and HDL‐cholesterol in Type 2 diabetes

M. Hermans, M. Buysschaert, S. Van Lerberghe, 2002, Diabetic medicine : a journal of the British Diabetic Association.

CLINICAL, BIOPHYSICAL AND BIOCHEMICAL VARIABLES FROM AFRICAN-HERITAGE SUBJECTS WITH TYPE 2 DIABETES

M. Hermans, M. Buysschaert, C. Dumont, 2002, Acta clinica Belgica.

Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.

M. Hermans, M. Buysschaert, P. Oriot, 2011, Annales d'endocrinologie.

Prospective screening for biopsy proven coeliac disease, autoimmunity and malabsorption markers in Belgian subjects with Type 1 diabetes

M. Hermans, M. Buysschaert, J. Tomasi, 2005, Diabetic medicine : a journal of the British Diabetic Association.

The permissive effect of glucose, tolbutamide and high K+ on arginine stimulation of insulin release in isolated mouse islets

M. Hermans, J. Henquin, W. Schmeer, 1987, Diabetologia.

Reported Rates, Incentives, and Effectiveness of Major Vaccinations in 501 Attendees at Two Diabetes Clinics

M. Hermans, M. Buysschaert, J. Donckier, 1997, Diabetes Care.

Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.

M. Jadoul, M. Hermans, S. Aydın, 2016, Diabetes & metabolism.

Glucose-, calcium- and concentration-dependence of acetylcholine stimulation of insulin release and ionic fluxes in mouse islets.

M. Hermans, J. Henquin, M. García, 1988, The Biochemical journal.

Comparative performance of serum cystatin-c versus serum creatinine in diabetic subjects.

M. Hermans, M. Buysschaert, P. Wallemacq, 2003, Diabetes & metabolism.

Relative Importance of Extracellular and Intracellular Ca2+ for Acetylcholine Stimulation of Insulin Release in Mouse Islets

M. Hermans, J. Henquin, M. Hermans, 1989, Diabetes.

Insulin release has no absolute requirement for extracellular monovalent ions

M. Hermans, J. Henquin, M. Hermans, 1986, FEBS letters.

The MTHFR C677T polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes

J. Gala, M. Hermans, M. Buysschaert, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Reply from M.P. Hermans, P. Selvais and M. van Ypersele de Strihou

M. Hermans, M. Hermans, P. Selvais, 1995 .

Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.

A. Pasquet, J. Vanoverschelde, J. Kefer, 2008, Diabetes & metabolism.

Erectile dysfunction and lower androgenicity in type 1 diabetic patients.

J. Jamart, M. Hermans, M. Buysschaert, 2001, Diabetes & metabolism.

THERAPY, GLYCAEMIC CONTROL AND COMPLICATIONS IN TYPE 1 DIABETIC PATIENTS : RESULTS FROM A SINGLE CENTRE COHORT OF 465 SUBJECTS

M. Hermans, M. Buysschaert, M. Hermans, 2001, Acta clinica Belgica.

NON-PHARMACOLOGICAL MANAGEMENT OF TYPE 2 DIABETES

M. Hermans, M. Buysschaert, 2004, Acta clinica Belgica.

Do high ferritin levels confer lower cardiovascular risk in men with Type 2 diabetes?

M. Hermans, M. Rousseau, M. Rousseau, 2010, Diabetic medicine : a journal of the British Diabetic Association.

Detection of Low‐Range Diabetic Micro‐albuminuria: Micral‐Test® Revisited

J. Ketelslegers, M. Hermans, P. Selvais, 1994, Diabetic Medicine.

Effects of chloride deficiency on the pancreatic B-cell response to acetylcholine.

M. Hermans, J. Henquin, W. Schmeer, 1991, Biochimica et Biophysica Acta.

Role of the decrease in ionized calcium in the inhibition of insulin release by chloride-free solutions.

M. Hermans, J. Henquin, M. Gerard, 1986, Biochimica et biophysica acta.

Is there a role for osmotic events in the exocytotic release of insulin?

M. Hermans, J. Henquin, 1986, Endocrinology.

Micro- and macrovascular complications and hyperhomocysteinaemia in type 1 diabetic patients.

J. Jamart, M. Hermans, M. Buysschaert, 2001, Diabetes & Metabolism.

C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemia.

J. Gala, M. Hermans, M. Buysschaert, 2004, Diabetes & metabolism.

DIABETES AND THE ENDOTHELIUM

M. Hermans, M. Hermans, 2007, Acta clinica Belgica.

Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.

M. Hermans, M. Buysschaert, 1999, Acta clinica Belgica.

[Endocrine complications of genetic hemochromatosis].

M. Hermans, M. Buysschaert, I. Paris, 1999, Acta clinica Belgica.